Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 24, 2011

View Archived Issues

Monoclonal antibody recognizes human embryonic stem cells with teratoma-forming potential

FDA provides draft guidelines on medical device approval and biomarker qualification

Omecamtiv mecarbil improves cardiac function in phase II study

Scientists isolate broadly neutralizing antibodies against HIV

New corticotropin-releasing factor CRF1 receptor antagonists disclosed

Swiss research team prepares novel chemokine CXCR7 receptor agonists

NovaDel signs agreement with Rechon Life Science for Zolpimist

FDA approves FISH-based in vitro diagnostic test for chronic lymphocytic leukemia

Allergan patents new cannabinoid CB2 receptor agonists

Novel epidermal growth factor receptor inhibitors synthesized by Chinese company

Chinese teams disclose new protein kinase inhibitors

Vertex presents novel protein kinase C inhibitors

Health Canada accepts NDS for lurasidone

Phase II trial of Adcetris in CD30-positive non-Hodgkin's lymphoma begins

Helsinn Therapeutics enrolls first patient in anamorelin phase III program

Mayo Clinic receives grant to investigate genetic risk of heart and blood vessel diseases

Thermo Fisher Scientific acquires Phadia

EP-217609 obtains European orphan drug status

Vernalis begins dosing in phase I trial of Parkinson's disease candidate

FDA sets PDUFA date for Amgen's sBLA for Xgeva

BiondVax Pharmaceuticals commences new phase II study of Multimeric-001 influenza vaccine

BMS submits applications in Japan for additional indications for two anticancer drugs

Recruitment begins in phase III Botox trial in patients with stroke

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Anti-C5aR1 antibodies linked to outcomes in giant cell arteritis
BioWorld Science
More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...